Visby Medical™, a leader in rapid, at-home polymerase chain reaction (PCR) diagnostics, today announced it has raised approximately $55 million, with the potential to reach $65 million, in its latest financing round led by Catalio Capital Management. The round also saw participation from existing investors including ND Capital, Cedars Sinai Medical Center, Blue Water Life Science Advisors, Pitango Ventures and John Doerr.

Visby Medical™，快速家用聚合酶链反应 (PCR) 诊断领域的领导者，今天宣布在其最新一轮由Catalio Capital Management领投的融资中筹集了约5500万美元，并有可能达到6500万美元。此轮融资还获得了现有投资者的参与，包括ND Capital、Cedars Sinai医疗中心、Blue Water Life Science Advisors、Pitango Ventures和John Doerr。

The funds will accelerate the launch and distribution of Visby Medical's recently FDA-authorized at-home Women's Sexual Health Test, further establishing the company's strategic focus as the premier at-home testing company..

这笔资金将加速Visby Medical最近获得FDA授权的女性性健康家庭检测产品的上市和分销，进一步巩固该公司作为首屈一指的家庭检测公司的战略重点。

Founded in 2012, Visby Medical, Inc. is revolutionizing infectious disease diagnosis by empowering both physicians and patients to accurately test for infections anywhere, anytime, with laboratory accuracy. The company's proprietary technology platform delivers true PCR results in under 30 minutes through the world's first instrument-free, single-use PCR tests that fit in the palm of your hand.

Visby Medical, Inc. 成立于2012年，正在通过使医生和患者能够随时随地以实验室级的精确度进行感染检测，彻底改变传染病诊断。该公司的专有技术平台通过世界上首个无需仪器、一次性使用的掌上PCR检测，可在30分钟内提供真正的PCR结果。

Currently, Visby Medical offers FDA-cleared tests for sexually transmitted infections (STIs), available both in point-of-care settings and now directly to consumers at home, and respiratory infections (COVID-19, flu A and flu B), available for point-of-care settings. Visby Medical is actively expanding its platform with a wide range of future tests for the at-home and point-of-care markets..

目前，Visby Medical 提供经 FDA 批准的性传播感染（STI）检测，既可用于现场护理环境，也可直接面向家庭消费者；同时提供呼吸道感染（COVID-19、甲型流感和乙型流感）检测，适用于现场护理环境。Visby Medical 正在积极扩展其平台，为家庭和现场护理市场开发一系列未来的检测产品。